biOasis Technologies Inc  

(Public, CVE:BTI)   Watch this stock  
Find more results for BTI
-0.01 (-0.87%)
Jul 7 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.12 - 1.14
52 week 0.75 - 1.50
Open 1.14
Vol / Avg. 24,250.00/30,764.00
Mkt cap 50.31M
P/E     -
Div/yield     -
EPS -0.06
Shares 44.13M
Beta 0.30
Inst. own     -

Key stats and ratios

Q1 (Feb '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -116.72% -118.42%
Return on average equity -126.00% -129.04%
CDP Score - -


Suite 125, 10551 Shellbridge Way
+1-778-3833280 (Phone)
+1-604-2150091 (Fax)

Website links


biOasis Technologies Inc. (biOasis) is an early stage Canada-based biopharmaceutical company focused on research, development and commercialization of technologies and products intended for diagnosis and treatment of central nervous system (CNS) diseases, including brain cancer. The Company was engaged in the development of a vector, Transcend and Transcend pep for the transport of therapeutic agents across the blood brain barrier (BBB). Transcend Platform exploits the blood-brain barrier (BBB) penetrating properties of a recombinant soluble human protein known as melanotransferrin (also referred to as MTf or p97). The Company reported that Transcend pep effectively delivers siRNA across the blood-brain barrier and into brain cells. The Company also initiated studies to assess the therapeutic potential of BT2111 for the treatment of brain metastases of HER2+ breast cancer.

Officers and directors

Robin B. Hutchison Chairman of the Board, President, Chief Executive Officer
Age: 58
Judi Dalling Chief Financial Officer, Corporate Secretary
Ronald P Erickson Independent Director
Age: 71
H. Christian Fibiger P.hD. Independent Director
Age: 71
Greg D. Gubitz Independent Director
Age: 57
J. Michael Hutchison QC Independent Director
Age: 70
Terry Pearson Ph.D. Independent Director
Age: 68